How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,018 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

when doubled. ] Known serum testosterone ≤ 150 ng/dl or symptoms of hypogonadism (fatigue, hot flashes, hair loss, loss of muscle mass, osteoporosis, low libido, depression) prior to ADT initiation not explained by other medical co-morbidity OR history of testosterone supplement. If questionable, serum testosterone level greater than 150 ng/dl can be used to exclude hypogonadism. Previous malignancy within 3 years other than non-melanomatous skin cancer and non-muscle invasive bladder cancer (...) Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2012 Clinical Trials

202. Androgen actions on the human hair follicle: perspectives. (Abstract)

Androgen actions on the human hair follicle: perspectives. Androgens stimulate beard growth but suppress hair growth in androgenetic alopecia (AGA). This condition is known as 'androgen paradox'. Human pilosebaceous units possess enough enzymes to form the active androgens testosterone and dihydrotestosterone. In hair follicles, 5α-reductase type 1 and 2, androgen receptors (AR) and AR coactivators can regulate androgen sensitivity of dermal papillae (DP). To regulate hair growth, androgens (...) stimulate production of IGF-1 as positive mediators from beard DP cells and of TGF-β1, TGF-β2, dickkopf1 and IL-6 as negative mediators from balding DP cells. In addition, androgens enhance inducible nitric oxide synthase from occipital DP cells and stem cell factor for positive regulation of hair growth in beard and negative regulation of balding DP cells. Moreover, AGA involves crosstalk between androgen and Wnt/β-catenin signalling. Finally, recent data on susceptibility genes have provided us

2012 Experimental Dermatology

203. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Full Text available with Trip Pro

hyperandrogenism and idiopathic hirsutism.A multicenter prevalence survey included 592 consecutive premenopausal women (393 from Madrid, Spain and 199 from Bologna, Italy) reporting spontaneously for blood donation. Immediately before donation, we conducted clinical and biochemical phenotyping for androgen excess disorders. We determined the prevalence of (i) hirsutism, acne and alopecia as clinical signs of androgen excess and (ii) functional disorders of androgen excess, including PCOS, defined (...) by the National Institute of Child Health and Human Development/National Institute of Health criteria, idiopathic hyperandrogenism and idiopathic hirsutism.Regarding clinical signs of hyperandrogenism, hirsutism and acne were equally frequent [12.2% prevalence; 95% confidence interval (CI): 9.5-14.8%], whereas alopecia was uncommon (1.7% prevalence, 95% CI: 0.7-2.7%). Regarding functional disorders of androgen excess, PCOS and idiopathic hirsutism were equally frequent (5.4% prevalence, 95% CI: 3.6-7.2

2012 Human Reproduction

204. Effects of topical application of EGCG on testosterone-induced hair loss in a mouse model. Full Text available with Trip Pro

 < 0.05). Topical EGCG down-regulated the T-induced expression of androgen receptor but did not down-regulate 17β-hydroxysteroid dehydrogenase (HSD) and three β-HSD expression. Analysis using liquid chromatography tandem mass spectrometry (LC-MS/MS) on serum and tissue samples revealed no significant difference in T and dihydrotestosterone concentrations between the T-injected and T + EGCG groups. Thus, we found that T injection in a mouse model induces hair loss by apoptosis of the hair follicles (...) Effects of topical application of EGCG on testosterone-induced hair loss in a mouse model. We investigated the effect of topical epigallocatechin-3-gallate (EGCG) on testosterone (T)-induced hair loss in mice. Marked hair loss was observed at the T-injected site, and topical EGCG significantly reduced the hair loss (P < 0.05). TUNEL staining showed apoptosis of follicular epithelial cells in the T-injected groups where topical EGCG was found to significantly diminish T-induced apoptosis (P

2011 Experimental Dermatology

205. Alopecia

variant of lichen planopilaris. Etiology The alopecias comprise a large group of disorders with multiple and varying etiologies ( ). The most common cause of alopecia is Androgenetic alopecia (male-pattern or female-pattern hair loss) Androgenetic alopecia is an androgen-dependent hereditary disorder in which dihydrotestosterone plays a major role. This form of alopecia may eventually affect up to 80% of white men by the age of 70 (male-pattern hair loss) and about half of all women (female-pattern (...) number of broken hairs. Primary hair shaft abnormalities are usually obvious on microscopic examination of the hair shaft. Scalp biopsy is indicated when alopecia persists and diagnosis is in doubt. Biopsy may differentiate scarring from nonscarring forms. Specimens should be taken from areas of active inflammation, ideally at the border of a bald patch. Fungal and bacterial cultures may be useful. Daily hair counts can be done by the patient to quantify hair loss when the pull test is negative

2013 Merck Manual (19th Edition)

206. Androgenetic Alopecia in Fabry Disease

is to assess whether patients with the classic form of Fabry disease have significantly less androgenic alopecia (male pattern baldness). Condition or disease Fabry Disease Detailed Description: Objectives: To test the hypothesis that adult males with classic form of Fabry disease have a significantly lower incidence of androgenic alopecia than matched controls. Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or alpha-galactosidase A activity associated with no residual (...) enzyme activity and non-Fabry male controls of the same age range and the same number of non-Fabry controls. Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in two groups of subjects. Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment

2011 Clinical Trials

207. Brain-derived nerve factor and neurotrophins in androgenetic alopecia. (Abstract)

Brain-derived nerve factor and neurotrophins in androgenetic alopecia. Several growth factors and cytokines have been shown to be involved in normal hair cycling as well as in androgenetic alopecia (AGA). However, the molecular cascades in AGA downstream from androgen receptor activation are far from being fully elucidated.We sought to determine the difference in the protein expression of growth factors/cytokines in balding vs. nonbalding scalp specimens from the same individuals affected (...) (P < 0·001). Expression of neurotrophin-3 and of β-nerve growth factor was also upregulated. On the other hand, protein expression of insulin-like growth factor-1 and its binding proteins as well as of the vascular endothelial growth factor family were significantly downregulated in the balding scalp.Neurotrophic factors, especially BDNF, may be important in mediating the effects of androgens on hair follicles, serving as a negative regulatory control signal. Further studies may lead to novel

2011 British Journal of Dermatology

208. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. (Abstract)

Androgenetic alopecia as an early marker of benign prostatic hyperplasia. Androgenetic alopecia (AGA) and benign prostatic hyperplasia are both androgen-dependent entities that respond to the blocking of 5-alpha-reductase.The objective of this study was to determine whether prostatic volumes and urinary flow changes were higher in patients with early-onset AGA than in healthy control subjects.This was an observational case-control study of 87 men: 45 with early-onset AGA diagnosed

2011 Journal of American Academy of Dermatology

209. Female Pattern Hair Loss in Complete Androgen Insensitivity Syndrome. (Abstract)

Female Pattern Hair Loss in Complete Androgen Insensitivity Syndrome. Female pattern hair loss, also known as female androgenetic alopecia, is generally regarded as an androgen-dependent disorder representing the female counterpart of male balding. We describe female pattern hair loss occurring in a patient with complete androgen insensitivity syndrome suggesting that mechanisms other than direct androgen action contribute to this common form of hair loss in women.

2010 British Journal of Dermatology

210. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Full Text available with Trip Pro

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. BACKGROUND: Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease (...) , and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation. METHODS: A 12-week double

2011 Journal of cachexia, sarcopenia and muscle Controlled trial quality: predicted high

211. Partial androgen insensitivity syndrome

is indicated when secondary terminal hair is present, whereas grade 7 is indicated when it is absent. The can be used in conjunction with the traditional three classes of AIS to provide additional information regarding the degree of genital masculinization, and is particularly useful when the diagnosis is PAIS. Left , 19-year-old man with grade 3 PAIS before initiation of androgen therapy. Right , Habitus after 3.5 years of androgen treatment. Partial androgen insensitivity syndrome is diagnosed when (...) Partial androgen insensitivity syndrome Partial androgen insensitivity syndrome - Wikipedia Partial androgen insensitivity syndrome From Wikipedia, the free encyclopedia Partial androgen insensitivity syndrome Other names Partial androgen resistance syndrome results when the function of the (AR) is impaired. The AR protein (pictured) mediates the effects of androgens in the human body. Partial androgen insensitivity syndrome ( PAIS ) is a condition that results in the partial inability

2012 Wikipedia

212. Androgenic hair

Androgenic hair Body hair - Wikipedia Body hair From Wikipedia, the free encyclopedia (Redirected from ) Body hair Hair on the Distribution of body hair in women and men [ ] Body hair , or androgenic hair , is the that develops on the during and after . It is differentiated from the and less visible , which are much finer and lighter in color. The growth of androgenic hair is related to the level of (often referred to as male ) and the density of androgen receptors in the dermal papillae. Both (...) hair, such as the first growth of on a male and female 's previously smooth chin; although it may appear thinner on the female. Androgenic hair follows the same as the hair that grows on the scalp, but with a shorter and longer . While the anagen phase for the hair on one's head lasts for years, the androgenic hair growth phase for body hair lasts a few months. The telogen phase for body hair lasts close to a year. [ ] This shortened growing period and extended dormant period explains why the hair

2012 Wikipedia

213. Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia

in women may identify the group that will respond. This study is designed to test the impact of finasteride therapy on hair loss in postmenopausal women. Condition or disease Intervention/treatment Phase Androgenetic Alopecia Drug: Finasteride Phase 1 Detailed Description: Androgen sensitivity in the cell is determined by the number of Cytosine-Adenine-Guanine repeats in the Androgen Receptor gene. Lower CAG repeats have been associated in previous studies with androgenic conditions such as acne (...) Posted : January 20, 2010 Last Update Posted : January 20, 2010 Sponsor: HairDx, LLC Information provided by: HairDx, LLC Study Details Study Description Go to Brief Summary: Previous studies of finasteride treatment in women with hair loss have failed to show positive results, yet, some women have responded anecdotally. Given that polymorphisms of the androgen receptor gene which confer androgen sensitivity impact male response to finasteride therapy, it was hypothesized that the same polymorphism

2010 Clinical Trials

214. Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. (Abstract)

Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. The gene encoding the androgen receptor (AR) is associated with male pattern baldness (androgenetic alopecia - AGA). In case-control and family analyses, we mapped AR and the adjacent intergenic regions. We found evidence for association with two independent loci, one upstream and previously described and the other downstream and apparently novel. The haplotype comprising these SNPs

2010 Experimental Dermatology

215. A comparative study of dyslipidaemia in men and woman with androgenic alopecia. Full Text available with Trip Pro

A comparative study of dyslipidaemia in men and woman with androgenic alopecia. Several studies have analyzed the relationship between androgenetic alopecia and cardiovascular disease (mainly heart disease). However few studies have analyzed lipid values in men and women separately. This case-control study included 300 patients consecutively admitted to an outpatient clinic, 150 with early onset androgenetic alopecia (80 males and 70 females) and 150 controls (80 males and 70 females (...) ) with other skin diseases. Female patients with androgenic alopecia showed significant higher triglycerides values (123.8 vs 89.43 mg/dl, p = 0.006), total cholesterol values (196.1 vs 182.3 mg/dl, p = 0.014), LDL-C values (114.1 vs 98.8 mg/dl, p = 0.0006) and lower HDL-C values (56.8 vs 67.7 mg/dl, p <0.0001) versus controls respectively. Men with androgenic alopecia showed significant higher triglycerides values (159.7 vs 128.7 mg/dl, p = 0.04) total cholesterol values (198.3 vs 181.4 mg/dl, p = 0.006

2010 Acta Dermato-Venereologica

216. Menopause

broken or bruised. The loss of thickness and elasticity is largely due to a decline in collagen levels. Other symptoms of connective tissue atrophy are brittle nails, hair loss, muscular aches and bone and joint pain. 3. Menopause symptomsROYAL COLLEGE OF NURSING 9 Long-term effects of oestrogen deficiency Cardiovascular disease Cardiovascular disease (CVD) is the collective term for angina, myocardial infarction, stroke, and peripheral vascular disease. Despite an overall reduction in CVD in recent (...) that practices may vary in each country and outside the UK. The information in this booklet has been compiled from professional sources, but its accuracy is not guaranteed. Whilst every effort has been made to ensure the RCN provides accurate and expert information and guidance, it is impossible to predict all the circumstances in which it may be used. Accordingly, the RCN shall not be liable to any person or entity with respect to any loss or damage caused or alleged to be caused directly or indirectly

2020 Royal College of Nursing

217. Bariatric surgery in Belgium: organisation and payment of care before and after surgery

²) or severe category II obesity (BMI 35- 35 kg/m². Weight loss is higher for RYGB and SG compared to LAGB. Observational data shows that the b ‘Remission’ does not equal definitive cure. weight loss is, in most cases, durable. After 10 years or more there is still, in most cases, a substantial weight loss. 1 Risk on obesity-related mortality Based on observational studies it can be concluded that the relative risk of premature mortality due to obesity related conditions may decrease with 30- 45%. 1 (...) and only include LAGB (for which the effect on OSAS is assumed to be lower compared to RYGB and SG). 1 Efficacy of bariatric surgery in adolescents The effect of bariatric surgery on weight loss in adolescents seems to be comparable to that documented in studies in adults. Yet the evidence is only based on 1 RCT (LAGB versus conservative treatment, patients aged 14-18 years). Two years after surgery, the mean weight loss in the LAGB group was 34.6 kg (95% CI: 30.2-39.0), with a mean BMI change of 12.7

2020 Belgian Health Care Knowledge Centre

218. Polycystic ovary syndrome

hypertension scalp hair loss oily skin or excessive sweating acanthosis nigricans family history of PCOS premature adrenarche low birth weight fetal androgen exposure obesity environmental endocrine disruptors Diagnostic investigations serum total and free testosterone serum dehydroepiandrosterone sulfate (DHEAS) serum 17-hydroxyprogesterone serum prolactin serum thyroid-stimulating hormone oral glucose tolerance test fasting lipid panel serum androstenedione pelvic ultrasound basal body temperature (...) hyper-androgenism or to induce fertility. Definition Polycystic ovary syndrome (PCOS) includes symptoms of hyper-androgenism, presence of hyper-androgenaemia, oligo-/anovulation, and polycystic ovarian morphology on ultrasound. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, et al., eds. Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific; 1992:377-84. The Rotterdam ESHRE/ASRM-sponsored PCOS

2019 BMJ Best Practice

219. Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer

a full submission assessed under the orphan medicine process abiraterone acetate (Zytiga ® ) is accepted for use within NHSScotland. Indication under review: abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy. Abiraterone acetate in combination with prednisone and androgen deprivation therapy demonstrated superiority over androgen deprivation (...) with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). 1 Dosing Information The recommended dose is 1,000mg (two 500mg tablets) as a single daily dose that must not be taken with food. The tablets should be taken at least one hour before or at least two hours after eating. For men with high risk mHSPC, abiraterone is to be taken with 5mg prednisone or prednisolone

2020 Scottish Medicines Consortium

220. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America

physical examination should be performed, with special attention to the following areas: • General: unexplained weight loss or gain, night sweats, fever, changes in body habitus • Vital signs: including height and weight • Skin: discoloration, rash, ulcers, or lesions • General: including body habitus, evidence of obesity, wasting, lipodystrophy, assessment of frailty, and ambulatory ability • Lymph nodes: localized or generalized enlargement of lymph nodes • Skin: seborrheic dermatitis, ecchymoses (...) , purpura, petechiae, Kaposi sarcoma, herpes simplex or zoster, psoriasis, molluscum contagiosum, onychomycosis, folliculitis, condylomata, cutaneous fungal infections, acanthosis • Eyes: vision change or loss • Lymph nodes: generalized or localized lymphadenopathy • Mouth: gum disease, ulcers, oral lesions, or pain • Eyes: retinal exudates or cotton wool spots, hemorrhages, pallor, icterus • Cardiopulmonary: chest pain, palpitations, wheezing, dyspnea, orthopnea • Cardiovascular: heart exam, peripheral

2020 Infectious Diseases Society of America

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>